As the panelists conclude their discussion about systemic lupus erythematosus (SLE) and hemophilia, they share their perspectives about the Affordable Care Act and its potential.
Patrick F. Fogarty, MD, Hugh Fatodu, RPh, MBA, and Maria Lopes, MD, MS, raise concerns about the affordability of healthcare.
Dr Fogarty hopes that despite high treatment costs, patients with hemophilia will have access to necessary drugs and specialty hemophilia treatment centers to receive the care that they require.
Mr Fatodu discusses the need for transparency when pharmaceutical companies review orphan drug prices and explains that the cost of a drug needs to be relative to its value.
Dr Lopes believes that professionals need to work collectively to define a product’s value and determine ways to minimize overall product waste.
Michelle Petri, MD, MPH, recognizes the issues that healthcare professionals face when treating patients with SLE and explains the importance for individualized therapy.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Specialty Drug Users to Gain Relief Under Medicare Reforms
May 16th 2025A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often represent a significant cost burden for Medicare Part D beneficiaries and which were selected for 2026 drug price negotiation under the Inflation Reduction Act.
Read More
Navigation and Clinician Payment Investments Enhance Colorectal Cancer Screening Benefits
May 15th 2025Investing in patient navigation and clinician incentives ensures colorectal cancer screening completion, improves early detection, reduces disparities, achieves cost savings, and advances population health for all stakeholders.
Read More